{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T19:26:37Z","timestamp":1794425197639,"version":"4.9.1"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T00:00:00Z","timestamp":1793923200000},"content-version":"vor","delay-in-days":66,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Virology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.coviro.2026.101564","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T23:54:31Z","timestamp":1781913271000},"page":"101564","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Combination adjuvants: clinical value and mechanisms of action"],"prefix":"10.1016","volume":"76","author":[{"given":"Natacha","family":"Madelon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4736-9003","authenticated-orcid":false,"given":"Arnaud M","family":"Didierlaurent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coviro.2026.101564_bib1","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1586\/14760584.6.5.723","article-title":"GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives","volume":"6","author":"Gar\u00e7on","year":"2007","journal-title":"Expert Rev Vaccin"},{"key":"10.1016\/j.coviro.2026.101564_bib2","doi-asserted-by":"crossref","first-page":"5937","DOI":"10.1016\/j.vaccine.2006.06.005","article-title":"Enhanced humoral and memory B cellular immunity using HPV16\/18 L1 VLP vaccine formulated with the MPL\/aluminium salt combination (AS04) compared to aluminium salt only","volume":"24","author":"Giannini","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2026.101564_bib3","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.vaccine.2004.06.006","article-title":"Safety and immunogenicity profile of an experimental hepatitis B vaccine adjuvanted with AS04","volume":"23","author":"Boland","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2026.101564_bib4","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.clim.2016.05.007","article-title":"Impact of adjuvants on CD4+ T cell and B cell responses to a protein antigen vaccine: results from a phase II, randomized, multicenter trial","volume":"169","author":"Leroux-Roels","year":"2016","journal-title":"Clin Immunol"},{"key":"10.1016\/j.coviro.2026.101564_bib5","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.4161\/hv.36117","article-title":"Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine and HPV-6\/11\/16\/18 vaccine in healthy women aged 18\u201345 years: follow-up through Month 48 in a Phase III randomized study","volume":"10","author":"Einstein","year":"2014","journal-title":"Human Vaccin Immunother"},{"key":"10.1016\/j.coviro.2026.101564_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0061825","article-title":"A randomized, observer-blinded immunogenicity trial of Cervarix\u00ae and Gardasil\u00ae Human Papillomavirus Vaccines in 12-15 year old girls","volume":"8","author":"Draper","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2026.101564_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2024.126215","article-title":"How has post-implementation surveillance of high-coverage vaccination with HPV16\/18-AS04 vaccine in England added to evidence about its cross-protective effects?","volume":"42","author":"Navarro-Torn\u00e9","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2026.101564_bib8","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-023-00613-1","article-title":"Systems serology-based comparison of antibody effector functions induced by adjuvanted vaccines to guide vaccine design","volume":"8","author":"Loos","year":"2023","journal-title":"npj Vaccin"},{"key":"10.1016\/j.coviro.2026.101564_bib9","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-023-00628-8","article-title":"Differences in HPV-specific antibody Fc-effector functions following Gardasil\u00ae and Cervarix\u00ae vaccination","volume":"8","author":"Roy","year":"2023","journal-title":"npj Vaccin"},{"key":"10.1016\/j.coviro.2026.101564_bib10","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/S2213-2600(21)00402-1","article-title":"Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan","volume":"9","author":"Hsieh","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.coviro.2026.101564_bib11","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S0140-6736(21)00241-5","article-title":"Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial","volume":"397","author":"Richmond","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2026.101564_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2019.108275","article-title":"Adjuvant effect of TLR7 agonist adsorbed on aluminum hydroxide (AS37): a phase I randomized, dose escalation study of an AS37-adjuvanted meningococcal C conjugated vaccine","volume":"209","author":"Gonzalez-Lopez","year":"2019","journal-title":"Clin Immunol"},{"key":"10.1016\/j.coviro.2026.101564_bib13","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.vaccine.2022.12.006","article-title":"Systems analysis of human responses to an aluminium hydroxide-adsorbed TLR7 agonist (AS37) adjuvanted vaccine reveals a dose-dependent and specific activation of the interferon-mediated antiviral response","volume":"41","author":"Siena","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2026.101564_bib14","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S1473-3099(20)30942-7","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial","volume":"21","author":"Ella","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.coviro.2026.101564_bib15","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20240604","article-title":"Use of 3M-052-AF with Alum adjuvant in HIV trimer vaccine induces human autologous neutralizing antibodies","volume":"221","author":"Hahn","year":"2024","journal-title":"J Exp Med"},{"key":"10.1016\/j.coviro.2026.101564_sbref16","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adi8039","article-title":"AS03 adjuvant enhances the magnitude, persistence, and clonal breadth of memory B cell responses to a plant-based COVID-19 vaccine in humans","volume":"9","author":"Grigoryan","year":"2024","journal-title":"Sci Immunol"},{"key":"10.1016\/j.coviro.2026.101564_sbref17","doi-asserted-by":"crossref","first-page":"17957","DOI":"10.1073\/pnas.1906613117","article-title":"Adjuvanted H5N1 influenza vaccine enhances both cross-reactive memory B cell and strain-specific naive B cell responses in humans","volume":"117","author":"Ellebedy","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.coviro.2026.101564_bib18","doi-asserted-by":"crossref","first-page":"7962","DOI":"10.1073\/pnas.0903181106","article-title":"Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine","volume":"106","author":"Galli","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.coviro.2026.101564_bib19","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2015.7916","article-title":"Effect of varying doses of a monovalent H7N9 influenza vaccine with and without AS03 and MF59 adjuvants on immune response: a randomized clinical trial","volume":"314","author":"Jackson","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.coviro.2026.101564_bib20","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1016\/j.vaccine.2019.06.039","article-title":"An indirect comparison meta-analysis of AS03 and MF59 adjuvants in pandemic influenza A(H1N1)pdm09 vaccines","volume":"37","author":"Hauser","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2026.101564_bib21","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41541-022-00524-7","article-title":"The antibody landscapes following AS03 and MF59 adjuvanted H5N1 vaccination","volume":"7","author":"Goll","year":"2022","journal-title":"npj Vaccin"},{"key":"10.1016\/j.coviro.2026.101564_bib22","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-36789-2","article-title":"Safety and immunogenicity of a thermostable ID93 + GLA-SE tuberculosis vaccine candidate in healthy adults","volume":"14","author":"Sagawa","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.coviro.2026.101564_bib23","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S2213-2600(20)30319-2","article-title":"Safety and immunogenicity of the adjunct therapeutic vaccine ID93 + GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trial","volume":"9","author":"Day","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.coviro.2026.101564_bib24","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S1473-3099(19)30739-X","article-title":"PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study","volume":"20","author":"Sirima","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.coviro.2026.101564_bib25","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-025-01261-3","article-title":"Safety and immunogenicity of the Sm-p80 GLA-SE schistosomiasis vaccine","volume":"10","author":"Jackson","year":"2025","journal-title":"npj Vaccin"},{"key":"10.1016\/j.coviro.2026.101564_bib26","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1016\/j.vaccine.2008.04.029","article-title":"The novel adjuvant IC31\u00ae strongly improves influenza vaccine-specific cellular and humoral immune responses in young adult and aged mice","volume":"26","author":"Riedl","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2026.101564_bib27","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S1473-3099(24)00814-4","volume":"25","author":"Borges","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.coviro.2026.101564_bib28","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1080\/14760584.2024.2382725","article-title":"Adjuvant system AS01: from mode of action to effective vaccines","volume":"23","author":"Roman","year":"2024","journal-title":"Expert Rev Vaccin"},{"key":"10.1016\/j.coviro.2026.101564_bib29","unstructured":"Tseng H.F. Effectiveness of the Adjuvanted Recombinant Zoster Vaccine in Adults \u226550 Years in the United States."},{"key":"10.1016\/j.coviro.2026.101564_sbref29","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/S0140-6736(24)00004-7","article-title":"Feasibility, safety, and impact of the RTS,S\/AS01E malaria vaccine when implemented through national immunisation programmes: evaluation of cluster-randomised introduction of the vaccine in Ghana, Kenya, and Malawi","volume":"403","author":"Asante","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2026.101564_bib31","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2026.101564_bib32","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1056\/NEJMoa1102287","article-title":"First results of phase 3 Trial of RTS,S\/AS01 malaria vaccine in african children","volume":"365","author":"S Clinical Trials Partnership","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2026.101564_bib33","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMoa2209604","article-title":"Respiratory syncytial virus prefusion F protein vaccine in older adults","volume":"388","author":"Papi","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2026.101564_bib34","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1093\/infdis\/jiaa300","article-title":"Immunogenicity of the adjuvanted recombinant zoster vaccine: persistence and anamnestic response to additional doses administered 10 years after primary vaccination","volume":"224","author":"Hastie","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2026.101564_sbref34","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103241","article-title":"Final analysis of the ZOE-LTFU trial to 11 years post-vaccination: efficacy of the adjuvanted recombinant zoster vaccine against herpes zoster and related complications","volume":"83","author":"Strezova","year":"2025","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.coviro.2026.101564_bib36","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1016\/S2214-109X(25)00415-2","article-title":"Effectiveness of the RTS,S\/AS01E malaria vaccine in a real-world setting over 1 year of follow-up after the three-dose primary schedule: an interim analysis of a phase 4 study in Ghana, Kenya, and Malawi","volume":"14","author":"Ndeketa","year":"2026","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.coviro.2026.101564_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1412732","article-title":"An innate immune signature induced by AS01- or AS03-adjuvanted vaccines predicts the antibody response magnitude and quality consistently over time","volume":"15","author":"Tasdighian","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.coviro.2026.101564_sbref37","doi-asserted-by":"crossref","DOI":"10.1016\/S2666-5247(24)00130-7","article-title":"Antibody mechanisms of protection against malaria in RTS,S-vaccinated children: a post-hoc serological analysis of phase 2 trial","volume":"5","author":"Kurtovic","year":"2024","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.coviro.2026.101564_bib39","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-025-01322-7","article-title":"ALFQ adjuvanted HIV-1 envelope protein vaccination elicits durable functional antibody and cellular responses in nonhuman primates","volume":"11","author":"Shrivastava","year":"2025","journal-title":"npj Vaccin"},{"key":"10.1016\/j.coviro.2026.101564_sbref39","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-017-0027-3","article-title":"Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFN\u03b3 response promoting vaccine immunogenicity","volume":"2","author":"Coccia","year":"2017","journal-title":"npj Vaccin"},{"key":"10.1016\/j.coviro.2026.101564_bib41","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1016\/j.vaccine.2012.01.088","article-title":"Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice","volume":"30","author":"Dendouga","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2026.101564_bib42","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.4049\/jimmunol.1400948","article-title":"Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells","volume":"193","author":"Didierlaurent","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.coviro.2026.101564_bib43","doi-asserted-by":"crossref","DOI":"10.1038\/srep39475","article-title":"Central role of CD169+ lymph node resident macrophages in the adjuvanticity of the QS-21 component of AS01","volume":"6","author":"Detienne","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.coviro.2026.101564_bib44","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/eji.201444543","article-title":"Squalene emulsion potentiates the adjuvant activity of the TLR4 agonist, GLA, via inflammatory caspases, IL-18, and IFN-\u03b3","volume":"45","author":"Desbien","year":"2015","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.coviro.2026.101564_sbref44","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aay8618","article-title":"Transcriptional profiles of adjuvanted hepatitis B vaccines display variable interindividual homogeneity but a shared core signature","volume":"12","author":"De Mot","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coviro.2026.101564_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.00943","article-title":"Different adjuvants induce common innate pathways that are associated with enhanced adaptive responses against a model antigen in humans","volume":"8","author":"Burny","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.coviro.2026.101564_bib47","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1441944","article-title":"Co-regulation of innate and adaptive immune responses induced by ID93+GLA-SE vaccination in humans","volume":"15","author":"Fiore-Gartland","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.coviro.2026.101564_sbref47","doi-asserted-by":"crossref","DOI":"10.1172\/JCI174144","article-title":"Innate immune cell activation by adjuvant AS01 in human lymph node explants is age independent","volume":"134","author":"Stylianou","year":"2024","journal-title":"J Clin Investig"},{"key":"10.1016\/j.coviro.2026.101564_bib49","article-title":"Emulsion and liposome-based adjuvanted R21 vaccine formulations mediate protection against malaria through distinct immune mechanisms","volume":"4","author":"Reinke","year":"2023","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.coviro.2026.101564_sbref49","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.115938","article-title":"Ex vivo model of functioning human lymph node reveals role for innate lymphocytes and stroma in response to vaccine adjuvant","volume":"44","author":"Fergusson","year":"2025","journal-title":"Cell Rep"},{"key":"10.1016\/j.coviro.2026.101564_bib51","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abf1152","article-title":"A particulate saponin\/TLR agonist vaccine adjuvant alters lymph flow and modulates adaptive immunity","volume":"6","author":"Silva","year":"2021","journal-title":"Sci Immunol"},{"key":"10.1016\/j.coviro.2026.101564_bib52","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/j.vaccine.2019.02.015","article-title":"Inflammatory parameters associated with systemic reactogenicity following vaccination with adjuvanted hepatitis B vaccines in humans","volume":"37","author":"Burny","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2026.101564_bib53","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41590-024-02036-z","article-title":"System vaccinology analysis of predictors and mechanisms of antibody response durability to multiple vaccines in humans","volume":"26","author":"Cortese","year":"2025","journal-title":"Nat Immunol"},{"key":"10.1016\/j.coviro.2026.101564_bib54","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1073\/pnas.1519690113","article-title":"Systems biology of immunity to MF59-adjuvanted versus nonadjuvanted trivalent seasonal influenza vaccines in early childhood","volume":"113","author":"Nakaya","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.coviro.2026.101564_bib55","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-023-00702-1","article-title":"Memory-like innate response to booster vaccination with MF-59 adjuvanted influenza vaccine in children","volume":"8","author":"Kazmin","year":"2023","journal-title":"npj Vaccin"},{"key":"10.1016\/j.coviro.2026.101564_bib56","unstructured":"Akhtar A. Influenza Vaccine based on AS03-Adjuvanted Chimeric HA Induces Long-lived Stalk-specific Plasma Cells in Bone Marrow and Lymph Nodes of Nonhuman Primates."},{"key":"10.1016\/j.coviro.2026.101564_bib57","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.vaccine.2011.01.011","article-title":"Adjuvant system AS03 containing \u03b1-tocopherol modulates innate immune response and leads to improved adaptive immunity","volume":"29","author":"Morel","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2026.101564_bib58","doi-asserted-by":"crossref","first-page":"11169","DOI":"10.1073\/pnas.1107941108","article-title":"Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88","volume":"108","author":"Seubert","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.coviro.2026.101564_bib59","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-025-01130-z","article-title":"Emulsion adjuvant-induced uric acid release modulates optimal immunogenicity by targeting dendritic cells and B cells","volume":"10","author":"Lee","year":"2025","journal-title":"npj Vaccin"},{"key":"10.1016\/j.coviro.2026.101564_bib60","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-018-0058-4","article-title":"Activation of the endoplasmic reticulum stress sensor IRE1\u03b1 by the vaccine adjuvant AS03 contributes to its immunostimulatory properties","volume":"3","author":"Givord","year":"2018","journal-title":"npj Vaccin"},{"key":"10.1016\/j.coviro.2026.101564_bib61","doi-asserted-by":"crossref","first-page":"6186","DOI":"10.4049\/jimmunol.0901474","article-title":"AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity","volume":"183","author":"Didierlaurent","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.coviro.2026.101564_bib62","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1623405","article-title":"AS04 drives superior cross-protective antibody response by increased NOTCH signaling of dendritic cells and proliferation of memory B cells","volume":"16","author":"D\u2019Onofrio","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.coviro.2026.101564_bib63","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1182\/bloodadvances.2017011411","article-title":"Innate transcriptional effects by adjuvants on the magnitude, quality, and durability of HIV envelope responses in NHPs","volume":"1","author":"Francica","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.coviro.2026.101564_bib64","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal2094","article-title":"Vaccine priming is restricted to draining lymph nodes and controlled by adjuvant-mediated antigen uptake","volume":"9","author":"Liang","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coviro.2026.101564_bib65","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1182\/blood-2011-10-388579","article-title":"Distinct TLR adjuvants differentially stimulate systemic and local innate immune responses in nonhuman primates","volume":"119","author":"Kwissa","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.coviro.2026.101564_bib66","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/s41586-021-03530-2","article-title":"Adjuvanting a subunit COVID-19 vaccine to induce protective immunity","volume":"594","author":"Arunachalam","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2026.101564_bib67","doi-asserted-by":"crossref","DOI":"10.1038\/s43856-024-00488-w","article-title":"Immunogenicity and efficacy of VLA2001 vaccine against SARS-CoV-2 infection in male cynomolgus macaques","volume":"4","author":"Galhaut","year":"2024","journal-title":"Commun Med"},{"key":"10.1016\/j.coviro.2026.101564_bib68","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/s41586-021-03791-x","article-title":"Systems vaccinology of the BNT162b2 mRNA vaccine in humans","volume":"596","author":"Arunachalam","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2026.101564_bib69","article-title":"A systems immunology study comparing innate and adaptive immune responses in adults to COVID-19 mRNA and adenovirus vectored vaccines","volume":"4","author":"Ryan","year":"2023","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.coviro.2026.101564_bib70","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abp9961","article-title":"High\u2013temporal resolution profiling reveals distinct immune trajectories following the first and second doses of COVID-19 mRNA vaccines","volume":"8","author":"Rinchai","year":"2022","journal-title":"Sci Adv"},{"key":"10.1016\/j.coviro.2026.101564_bib71","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.immuni.2022.10.014","article-title":"Innate immune mechanisms of mRNA vaccines","volume":"55","author":"Verbeke","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.coviro.2026.101564_sbref70","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1016\/j.immuni.2021.11.001","article-title":"Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses","volume":"54","author":"Alameh","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.coviro.2026.101564_bib73","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-025-01124-x","article-title":"Ionizable lipid nanoparticles of mRNA vaccines elicit NF-\u03baB and IRF responses through toll-like receptor 4","volume":"10","author":"Zelkoski","year":"2025","journal-title":"npj Vaccin"},{"key":"10.1016\/j.coviro.2026.101564_sbref72","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41590-022-01163-9","article-title":"Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine","volume":"23","author":"Li","year":"2022","journal-title":"Nat Immunol"},{"key":"10.1016\/j.coviro.2026.101564_sbref73","doi-asserted-by":"crossref","first-page":"7461","DOI":"10.1016\/j.cell.2025.11.023","article-title":"Distinct components of mRNA vaccines cooperate to instruct efficient germinal center responses","volume":"188","author":"Casta\u00f1o","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.coviro.2026.101564_bib76","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aaz6893","article-title":"Impact of mRNA chemistry and manufacturing process on innate immune activation","volume":"6","author":"Nelson","year":"2020","journal-title":"Sci Adv"},{"key":"10.1016\/j.coviro.2026.101564_sbref75","article-title":"Innate immune responses against mRNA vaccine promote cellular immunity through IFN-\u03b2 at the injection site","volume":"15","author":"Kim","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.coviro.2026.101564_bib78","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2025.2477300","article-title":"Age-related changes in the immune system and challenges for the development of age-specific vaccines","volume":"57","author":"Doherty","year":"2025","journal-title":"Ann Med"},{"key":"10.1016\/j.coviro.2026.101564_bib79","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abq7378","article-title":"Precision adjuvants for pediatric vaccines","volume":"16","author":"Singh","year":"2024","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coviro.2026.101564_bib80","doi-asserted-by":"crossref","DOI":"10.1111\/tid.70053","article-title":"Vaccine adjuvants in the immunocompromised host: science, safety, and efficacy","volume":"27","author":"Hayek","year":"2025","journal-title":"Transplant Infect Dis"}],"container-title":["Current Opinion in Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625726000568?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625726000568?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T19:18:24Z","timestamp":1794424704000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879625726000568"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":80,"alternative-id":["S1879625726000568"],"URL":"https:\/\/doi.org\/10.1016\/j.coviro.2026.101564","relation":{},"ISSN":["1879-6257"],"issn-type":[{"value":"1879-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination adjuvants: clinical value and mechanisms of action","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coviro.2026.101564","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101564"}}